Interobserver variability for the WHO classification of pulmonary carcinoids

American Journal of Surgical Pathology

Volumn 38, Issue 10, 2014, Pages 1429-1436

  Swarts, Dorian R A ^a,m   Van Suylen, Robert Jan ^b   Den Bakker, Michael A ^c   Van Oosterhout, Matthijs F M ^d   Thunnissen, Frederik B J M ^e   Volante, Marco ^f   Dingemans, Anne Marie C ^a   Scheltinga, Marc R M ^g,l   Bootsma, Gerben P ^h   Pouwels, Harry M M ⁱ   Van Den Borne, Ben E E M ^j   Ramaekers, Frans C S ^a   Speel, Ernst Jan M ^a,k  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c Maasstad Hospital Rotterdam   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF TURIN   (Italy)

^g MÁXIMA MEDICAL CENTER   (Netherlands)

^h Sittard Geleen Heerlen   (Netherlands)

ⁱ VIECURI MEDICAL CENTER   (Netherlands)

^j CATHARINA HOSPITAL   (Netherlands)

^k MAASTRICHT UNIVERSITY   (Netherlands)

^l MAASTRICHT UNIVERSITY   (Netherlands)

^m UNIVERSITY OF YORK   (United Kingdom)

more..

Author keywords

Interobserver variation; Lung neuroendocrine tumors; MIB 1; Orthopedia homeobox; Typical and atypical carcinoids

Indexed keywords

HOMEODOMAIN PROTEIN; KI 67 ANTIGEN; NERVE PROTEIN; OTP PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY; CARCINOID; CELL PROLIFERATION; CHEMISTRY; CLASSIFICATION; CONSENSUS; EUROPE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MIDDLE AGED; MITOSIS INDEX; MORTALITY; MULTICENTER STUDY; NECROSIS; NOMENCLATURE; OBSERVER VARIATION; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; VERY ELDERLY; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOID TUMOR; CELL PROLIFERATION; CONSENSUS; EUROPE; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOTIC INDEX; NECROSIS; NERVE TISSUE PROTEINS; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TERMINOLOGY AS TOPIC; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84908568698     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000300     Document Type: Article

References (28)

1. Beasley MB, Thunnissen FB, Hasleton PhS, et al. Carcinoid tumour. In: Travis WD, Brambilla E, Muller-Harmelink HK, et al, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004:59-62.
2. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934-944.
3. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972;64:413-421.
4. Thunnissen FB, Ambergen AW, Koss M, et al. Mitotic counting in surgical pathology: sampling bias, heterogeneity and statistical uncertainty. Histopathology. 2001;39:1-8.
5. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol. 2000;31:1255-1265.
6. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70-76.
7. Garcia-Yuste M, Matilla JM, Cueto A, et al. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multicentric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg. 2007;31:192-197.
8. Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol. 2010;21(suppl 7):vii65-vii71.
9. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;119:1647-1651.
10. den Bakker MA, Willemsen S, Grunberg K, et al. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability. Histopathology. 2010;56:356-363.
11. Lee CH, Chang HK, Lee HW, et al. The interobserver variability for diagnosing pulmonary carcinoid tumor. Korean J Pathol. 2010;44:267-271.
12. Travis WD, Gal AA, Colby TV, et al. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol. 1998;29:272-279.
13. Warth A, Fink L, Fisseler-Eckhoff A, et al. Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. Virchows Arch. 2013;462:507-513.
14. Swarts DR, Claessen SM, Jonkers YM, et al. Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome. Am J Pathol. 2011;179:1129-1137.
15. Swarts DR, van Neste L, Henfling ME, et al. An exploration of pathways involved in lung carcinoid progression using gene expression profiling. Carcinogenesis. 2013;34:2726-2737.
16. Swarts DR, Henfling ME, Van Neste L, et al. CD44 and OTP are strong prognostic markers for pulmonary carcinoids. Clin Cancer Res. 2013;19:2197-2207.
17. Fleskens SA, Bergshoeff VE, Voogd AC, et al. Interobserver variability of laryngeal mucosal premalignant lesions: a histopathological evaluation. Mod Pathol. 2011;24:892-898.
18. Skov BG, Krasnik M, Lantuejoul S, et al. Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival. J Thorac Oncol. 2008;3:1410-1415.
19. Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta. 2012;1826:255-271.
20. Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol. 2001;12:1383-1391.
21. Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg. 2010;89:998-1005.
22. Tsuta K, Raso MG, Kalhor N, et al. Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer. 2011;71:34-41.
23. Righi L, Volante M, Rapa I, et al. Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch. 2007;451(suppl 1):S51-S59.
24. Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104:764-777.
25. Zahel T, Krysa S, Herpel E, et al. Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach. Virchows Arch. 2012;460:299-308.
26. Walts AE, Ines D, Marchevsky AM. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol. 2012;25:1258-1264.
27. Rindi G, Klersy C, Inzani F, et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer. 2014;21:1-16.
28. Tsuta K, Liu DC, Kalhor N, et al. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol. 2011;136:252-259.